{"success":true,"data":{"pressRelease":{"id":"30236","rtpr_id":"nGNX6qXZ4F","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Concealed Drug Limitation Risks: Levi & Korsinsky","author":"Globe Newswire","published_at":"2026-05-11T20:00:01.175Z","article_body":"NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces\nthat a securities class action has been filed against ImmunityBio, Inc.\n(NASDAQ: IBRX).\n\nYOU MAY BE AFFECTED IF YOU:\n* Purchased IBRX stock between January 19, 2026 and March 24, 2026\n* Lost money on your ImmunityBio investment\nSubmit your information to recover losses\n(https://www.globenewswire.com/Tracker?data=dQ_hyYInS55-d7STFF8mQ-kkDp-hVmqC8wFllo6TLneQIfJWMB7c2jncUwKPNKZTzQ-Azi43vKsuJqjfFC__2mw4f_PUcc639_-hH4GsNBKysbECBLUYaOgnyVA-WnGt-EhrAHy1Lz_tohkT2Q0pdDG_ykLZJjIPymXL8A_gCXx8QR9fx2vn3_K0CyqSwGzGnqFBHypyQfTT9O0sPBgN_A==)\nor contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.\n\nImmunityBio shareholders lost $1.98 per share, a 21% decline, after an FDA\nWarning Letter exposed what the agency called \"false or misleading\"\npromotional communications about the Company's lead drug, ANKTIVA. The stock\nclosed at $7.42 on March 24, 2026, down from $9.40 the prior session.\n\nWhat They Allegedly Knew\n\nThe securities action contends that when the Company's Executive Chairman\nappeared on a nationally broadcast podcast on January 19, 2026, he possessed\nknowledge that should have prevented the statements he made. ANKTIVA was\napproved solely for a specific type of bladder cancer. According to the\ncomplaint, bladder cancers represented only an estimated 4.2% of new cancer\ncases in 2025. Yet promotional communications characterized the drug as\ncapable of treating \"all cancers\" and described it as a “Cancer Therapeutic\nVaccine.” The FDA later determined these characterizations were false.\n\nThe complaint charges that the Company knew ANKTIVA's clinical trial,\nQUILT-3.032, was a single-arm study in only 77 patients, with a 62% complete\nresponse rate and no interpretable disease-free survival data. The cohort\nevaluating ANKTIVA as a single agent was stopped early for futility. Despite\nthese limitations, public communications allegedly presented the drug as a\nnear-universal cancer cure.\n\nThe Red Flags That Emerged\n\nThe action alleges several indicators that should have constrained public\nstatements about ANKTIVA's capabilities:\n* ANKTIVA's FDA approval was limited to BCG-unresponsive, high-risk,\nnon-muscle invasive bladder cancer with CIS, a narrow indication\n* The single-agent cohort (Cohort C) of the pivotal trial was terminated for\nfutility, meaning ANKTIVA alone showed insufficient efficacy\n* The drug's approved route of administration was intravesical only, yet\npromotional materials depicted subcutaneous injection\n* No clinical data existed supporting claims that ANKTIVA could prevent cancer\nor treat lung cancer after checkpoint inhibitor failure\n* The FDA's prescribing information described ANKTIVA as an IL-15 receptor\nagonist, not a vaccine, contradicting the claims used in the Company’s\npromotional materials\nInside Knowledge vs. Public Statements\n\nAs alleged in the complaint, the gap between what was known internally and\nwhat was communicated publicly is central to this securities action. The\nCompany's own prescribing information and clinical data contradicted the\npromotional claims. The FDA Warning Letter, dated March 13, 2026, stated these\nviolations were \"concerning from a public health perspective\" because\npromotional materials \"grossly misrepresent the benefits of Anktiva.\" The\nagency further noted the representations were \"particularly alarming\"\nregarding unapproved routes of administration.\n\n\"The timeline raises important questions about when certain risks were known\ninternally versus when they were disclosed to the investing public. The\nCompany's own clinical trial data and FDA-approved labeling stood in direct\ncontrast to the promotional claims being made to patients and investors\nalike,\" stated Joseph E. Levi, Esq.\n\nWhat Investors Were Not Told\n\nThe lawsuit maintains that shareholders purchasing IBRX securities during the\nClass Period were not informed that the Company's promotional activities\nviolated the Federal Food, Drug, and Cosmetic Act, that its lead product's\ncapabilities were being materially overstated, or that regulatory action was a\nforeseeable consequence. When the FDA Warning Letter became public on March\n24, 2026, the market corrected sharply.\n\nAct now to protect your rights\n(https://www.globenewswire.com/Tracker?data=p7LqCcIs_dsyh3u_JHsZY4MHH9gG_k6flXmwHkhQJAt4wLbI54TH9__tN1TKAkfctRwC6ikMUtTQR220rOwa0ybzXXTV3MQbwZr5dYm9iVEYx6s9d49n1riJ6b9XG-LzYKT2vs1IixuRKb4BGVPyUFmPr5NOnT9SAlZX8eQt2V3_zBOZ15gNk9MsFQ_h2KTl)\nor call Joseph E. Levi, Esq. at (212) 363-7500.\n\nAbout Levi & Korsinsky, LLP\n\nLevi & Korsinsky represents investors in securities class actions nationwide,\nwith a track record of recovering hundreds of millions for shareholders harmed\nby alleged corporate concealment. Ranked among ISS Top 50 for seven\nconsecutive years. Lead plaintiff applications must be submitted by May 26,\n2026.\n\nFrequently Asked Questions About the IBRX Lawsuit\n\nQ: When did ImmunityBio allegedly mislead investors? A: The class period runs\nfrom January 19, 2026 to March 24, 2026. The alleged fraud was revealed\nthrough the publicization of an FDA Warning Letter on March 24, 2026, causing\na 21% stock decline.\n\nQ: What specific misstatements does the IBRX lawsuit allege? A: The complaint\nalleges ImmunityBio made materially false or misleading statements regarding\nANKTIVA's capabilities, including claims it could treat \"all cancers,\" was a\n“vaccine” for cancer, and could be administered subcutaneously, when\nclinical data and FDA-approved labeling contradicted each of these\nrepresentations.\n\nQ: What do IBRX investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi &\nKorsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or\n(212) 363-7500. No immediate action is required to remain eligible as a class\nmember.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What if I already sold my IBRX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\\\n\nLevi & Korsinsky, LLP\\\n\nJoseph E. Levi, Esq.\\\n\nEd Korsinsky, Esq.\\\n\n33 Whitehall Street, 27th Floor\\\n\nNew York, NY 10004\\\n\njlevi@levikorsinsky.com\\\n\nTel: (212) 363-7500\\\n\nFax: (212) 363-7171\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d91bd4e6-7d18-43f7-a479-4f992242a82a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6qXZ4F","title":"IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Concealed Drug Limitation Risks: Levi & Korsinsky","author":"Globe Newswire","ticker":"IBRX","created":"2026-05-11T20:00:01.175Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces\nthat a securities class action has been filed against ImmunityBio, Inc.\n(NASDAQ: IBRX).\n\nYOU MAY BE AFFECTED IF YOU:\n* Purchased IBRX stock between January 19, 2026 and March 24, 2026\n* Lost money on your ImmunityBio investment\nSubmit your information to recover losses\n(https://www.globenewswire.com/Tracker?data=dQ_hyYInS55-d7STFF8mQ-kkDp-hVmqC8wFllo6TLneQIfJWMB7c2jncUwKPNKZTzQ-Azi43vKsuJqjfFC__2mw4f_PUcc639_-hH4GsNBKysbECBLUYaOgnyVA-WnGt-EhrAHy1Lz_tohkT2Q0pdDG_ykLZJjIPymXL8A_gCXx8QR9fx2vn3_K0CyqSwGzGnqFBHypyQfTT9O0sPBgN_A==)\nor contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.\n\nImmunityBio shareholders lost $1.98 per share, a 21% decline, after an FDA\nWarning Letter exposed what the agency called \"false or misleading\"\npromotional communications about the Company's lead drug, ANKTIVA. The stock\nclosed at $7.42 on March 24, 2026, down from $9.40 the prior session.\n\nWhat They Allegedly Knew\n\nThe securities action contends that when the Company's Executive Chairman\nappeared on a nationally broadcast podcast on January 19, 2026, he possessed\nknowledge that should have prevented the statements he made. ANKTIVA was\napproved solely for a specific type of bladder cancer. According to the\ncomplaint, bladder cancers represented only an estimated 4.2% of new cancer\ncases in 2025. Yet promotional communications characterized the drug as\ncapable of treating \"all cancers\" and described it as a “Cancer Therapeutic\nVaccine.” The FDA later determined these characterizations were false.\n\nThe complaint charges that the Company knew ANKTIVA's clinical trial,\nQUILT-3.032, was a single-arm study in only 77 patients, with a 62% complete\nresponse rate and no interpretable disease-free survival data. The cohort\nevaluating ANKTIVA as a single agent was stopped early for futility. Despite\nthese limitations, public communications allegedly presented the drug as a\nnear-universal cancer cure.\n\nThe Red Flags That Emerged\n\nThe action alleges several indicators that should have constrained public\nstatements about ANKTIVA's capabilities:\n* ANKTIVA's FDA approval was limited to BCG-unresponsive, high-risk,\nnon-muscle invasive bladder cancer with CIS, a narrow indication\n* The single-agent cohort (Cohort C) of the pivotal trial was terminated for\nfutility, meaning ANKTIVA alone showed insufficient efficacy\n* The drug's approved route of administration was intravesical only, yet\npromotional materials depicted subcutaneous injection\n* No clinical data existed supporting claims that ANKTIVA could prevent cancer\nor treat lung cancer after checkpoint inhibitor failure\n* The FDA's prescribing information described ANKTIVA as an IL-15 receptor\nagonist, not a vaccine, contradicting the claims used in the Company’s\npromotional materials\nInside Knowledge vs. Public Statements\n\nAs alleged in the complaint, the gap between what was known internally and\nwhat was communicated publicly is central to this securities action. The\nCompany's own prescribing information and clinical data contradicted the\npromotional claims. The FDA Warning Letter, dated March 13, 2026, stated these\nviolations were \"concerning from a public health perspective\" because\npromotional materials \"grossly misrepresent the benefits of Anktiva.\" The\nagency further noted the representations were \"particularly alarming\"\nregarding unapproved routes of administration.\n\n\"The timeline raises important questions about when certain risks were known\ninternally versus when they were disclosed to the investing public. The\nCompany's own clinical trial data and FDA-approved labeling stood in direct\ncontrast to the promotional claims being made to patients and investors\nalike,\" stated Joseph E. Levi, Esq.\n\nWhat Investors Were Not Told\n\nThe lawsuit maintains that shareholders purchasing IBRX securities during the\nClass Period were not informed that the Company's promotional activities\nviolated the Federal Food, Drug, and Cosmetic Act, that its lead product's\ncapabilities were being materially overstated, or that regulatory action was a\nforeseeable consequence. When the FDA Warning Letter became public on March\n24, 2026, the market corrected sharply.\n\nAct now to protect your rights\n(https://www.globenewswire.com/Tracker?data=p7LqCcIs_dsyh3u_JHsZY4MHH9gG_k6flXmwHkhQJAt4wLbI54TH9__tN1TKAkfctRwC6ikMUtTQR220rOwa0ybzXXTV3MQbwZr5dYm9iVEYx6s9d49n1riJ6b9XG-LzYKT2vs1IixuRKb4BGVPyUFmPr5NOnT9SAlZX8eQt2V3_zBOZ15gNk9MsFQ_h2KTl)\nor call Joseph E. Levi, Esq. at (212) 363-7500.\n\nAbout Levi & Korsinsky, LLP\n\nLevi & Korsinsky represents investors in securities class actions nationwide,\nwith a track record of recovering hundreds of millions for shareholders harmed\nby alleged corporate concealment. Ranked among ISS Top 50 for seven\nconsecutive years. Lead plaintiff applications must be submitted by May 26,\n2026.\n\nFrequently Asked Questions About the IBRX Lawsuit\n\nQ: When did ImmunityBio allegedly mislead investors? A: The class period runs\nfrom January 19, 2026 to March 24, 2026. The alleged fraud was revealed\nthrough the publicization of an FDA Warning Letter on March 24, 2026, causing\na 21% stock decline.\n\nQ: What specific misstatements does the IBRX lawsuit allege? A: The complaint\nalleges ImmunityBio made materially false or misleading statements regarding\nANKTIVA's capabilities, including claims it could treat \"all cancers,\" was a\n“vaccine” for cancer, and could be administered subcutaneously, when\nclinical data and FDA-approved labeling contradicted each of these\nrepresentations.\n\nQ: What do IBRX investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi &\nKorsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or\n(212) 363-7500. No immediate action is required to remain eligible as a class\nmember.\n\nQ: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the\ninvestor appointed by the court to represent the entire class. Lead plaintiffs\nare typically investors with the largest documented losses. Being appointed\ndoes not increase individual recovery but gives direct oversight of how the\ncase is run.\n\nQ: What if I already sold my IBRX shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: Do I need to go to court or give testimony? A: No. The overwhelming\nmajority of class members never appear in court or give depositions. You\nsubmit a claim form to receive your portion of recovery.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\\\n\nLevi & Korsinsky, LLP\\\n\nJoseph E. Levi, Esq.\\\n\nEd Korsinsky, Esq.\\\n\n33 Whitehall Street, 27th Floor\\\n\nNew York, NY 10004\\\n\njlevi@levikorsinsky.com\\\n\nTel: (212) 363-7500\\\n\nFax: (212) 363-7171\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d91bd4e6-7d18-43f7-a479-4f992242a82a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-11T20:00:01.228733387Z","server_sent_at_ms":1778529601228},"received_at":"2026-05-11T20:00:01.468Z","source_url":null},"analysis":{"id":"22399","press_release_id":"30236","analysis_json":{"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky, LLP announced a securities class action against ImmunityBio, Inc. (NASDAQ: IBRX) for alleged misstatements about its lead drug, ANKTIVA.\n\nThe lawsuit claims that ImmunityBio's Executive Chairman made false or misleading statements about ANKTIVA's capabilities, including claims it could treat 'all cancers' and was a 'vaccine' for cancer, when clinical data and FDA-approved labeling contradicted these claims.\n\nThe FDA Warning Letter, dated March 13, 2026, exposed these violations, leading to a 21% stock decline from $9.40 to $7.42 on March 24, 2026.\n\nInvestors who purchased IBRX stock between January 19, 2026 and March 24, 2026 and suffered losses are encouraged to contact the firm for a free, no-obligation evaluation.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"The timeline raises important questions about when certain risks were known internally versus when they were disclosed to the investing public. The Company's own clinical trial data and FDA-approved labeling stood in direct contrast to the promotional claims being made to patients and investors alike","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney"},{"name":"Ed Korsinsky, Esq.","role":"attorney"}],"products":["ANKTIVA","zenvigatumab"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.98","context":"per-share loss after FDA Warning Letter"},{"amount":"$7.42","context":"stock closing price on March 24, 2026"},{"amount":"$9.40","context":"stock closing price on March 23, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Levi & Korsinsky. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"IBRX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky, LLP announced a securities class action against ImmunityBio, Inc. (NASDAQ: IBRX) for alleged misstatements about its lead drug, ANKTIVA.\n\nThe lawsuit claims that ImmunityBio's Executive Chairman made false or misleading statements about ANKTIVA's capabilities, including claims it could treat 'all cancers' and was a 'vaccine' for cancer, when clinical data and FDA-approved labeling contradicted these claims.\n\nThe FDA Warning Letter, dated March 13, 2026, exposed these violations, leading to a 21% stock decline from $9.40 to $7.42 on March 24, 2026.\n\nInvestors who purchased IBRX stock between January 19, 2026 and March 24, 2026 and suffered losses are encouraged to contact the firm for a free, no-obligation evaluation.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney"},{"name":"Ed Korsinsky, Esq.","role":"attorney"}],"products":["ANKTIVA","zenvigatumab"],"companies":[{"name":"ImmunityBio, Inc.","ticker":"IBRX"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$1.98","context":"per-share loss after FDA Warning Letter"},{"amount":"$7.42","context":"stock closing price on March 24, 2026"},{"amount":"$9.40","context":"stock closing price on March 23, 2026"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a76fb3b19e8e8b7b","schema_hash":"sha256:8658c370b800cf3d","created_at":"2026-05-11T20:24:44.050Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":82901,"modelName":"george-droid-qwen-72b"}}